177Lu-PP-F11N

N/A

Report date: 2025/11/20 16:01:04

NME

Base Information

Drug Name177Lu-PP-F11N

Drug Alias Name177Lu-PP-F11N

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionCholecystokinin B receptor antagonists

TargetsCholecystokinin B receptor

Therapy Area/IndicationsMedullary thyroid cancer (MTC)Neuroendocrine Tumors

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Hospital Basel

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Hospital Basel

Inactive CompaniesN/A

Active IndicationsMedullary thyroid cancer (MTC)Neuroendocrine Tumors

Inactive IndicationsN/A

Other Information

ATC CodeN/A